Table 3.
Antimicrobial susceptibility of the 87 ESBL-Ec isolated from soldiers in June and November
| Antimicrobialsa,b | R n (%) |
Ic n (%) |
S n (%) |
|---|---|---|---|
| AMX | 87 (100.0) | ||
| AMC | 19 (21.8) | 68 (78.2) | |
| SAM | 40 (46.0) | 47 (54.0) | |
| PIP | 87 (100.0) | ||
| TZP | 87 (100.0) | ||
| TEM | 87 (100.0) | ||
| CXM | 87 (100.0) | ||
| CTXc | 84 (96.6) | 2 (2.3) | 1 (1.1) |
| CAZ | 40 (46.0) | 46 (52.9) | 1 (1.1) |
| CZA | 87 (100.0) | ||
| FEP | 86 (98.9) | 1 (1.1) | |
| CTA | 87 (100.0) | ||
| ATM | 82 (94.3) | 4 (4.6) | 1 (1.1) |
| ETP | 87 (100.0) | ||
| IPM | 87 (100.0) | ||
| MEMd | 87 (100.0) | ||
| AMK | 3 (3.4) | 84 (96.6) | |
| GEN | 9 (10.3) | 78 (89.7) | |
| TOB | 11 (12.6) | 76 (87.4) | |
| CIPc | 32 (36.8) | 36 (41.4) | 19 (21.8) |
| LEV | 30 (34.5) | 5 (5.7) | 52 (59.8) |
| DOX | 39 (44.8) | 15 (17.2) | 33 (37.9) |
| TGC | 7 (8.0) | 80 (92.0) | |
| TRM | 75 (86.2) | 12 (13.8) | |
| SXT | 70 (80.5) | 1 (1.1) | 16 (18.4) |
| FUR | 87 (100.0) | ||
| FOSe | 87 (100.0) | ||
| CMP | 10 (11.5) | 77 (88.5) | |
| COL | 1 (1.1) | 86 (98.9) |
aAbbreviations: AMX amoxicillin, AMC amoxicillin/clavulanic acid, SAM ampicillin/sulbactam, PIP piperacillin, TZP piperacillin/tazobactam, TEM temocillin, CXM cefuroxime, CTX cefotaxime, CAZ ceftazidime, CZA ceftazidime/avibactam, FEP cefepime, CTA ceftolozane/tazobactam, ATM aztreonam, ETP ertapenem, IPM imipenem, MEM meropenem, AMK amikacin, GEN gentamicin, TOB tobramycin, CIP ciprofloxacin, LEV levofloxacin, DOX doxycycline, TGC tigecycline, TRM trimethoprim, SXT trimethoprim/sulfamethoxazole, FUR nitrofurantoin, FOS fosfomycin, CMP chloramphenicol, COL colistin
bThe in-house BMD assay included: AMX, AMC, SAM, TEM, CXM, FEP, ATM, ETP, GEN, TOB, DOX, TRM, and FUR. The Micronaut MDR MRGN assay contained PIP, TZP, CTX, CAZ, CZA, CTA, IPM, MEM, AMK, CIP, LEV, TGC, SXT, FOS, CMP, and COL
cSusceptible increased exposure
dCTX, MEM, CIP–MIC interpretation for indications other than meningitis
eFOS: interpretation for the iv formulation